Poitevin CA, Ramos PR, Chávez NJ

Language: Spanish
References: 13
Page: 6-8
PDF size: 132.44 Kb.

ABSTRACT

The standard treatment for early breast cancer is a conservative management and postoperative radiation. In this review article, the most current evidence on local control and survival, boost, lymph nodes radiation, hypofractionation and targeted therapy association is included.

REFERENCES

1. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)*. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomized trials. Lancet. 2011; 378: 1707-1716.

2. Bartelink H, Philippe Maingon P, Poortmans P, Weltens C, Fourquet A, Jager J et al, on behalf of the European Organisation for Research and Treatment of Cancer Radiation Oncology and Breast Cancer Groups. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. Lancet Oncol. 2015; 16: 47-56.

3. Strnad V, Hannoun-Levi JM, Guinot JL, Lössl K, Kauer-Dorner D, Resch A et al, on behalf of Working Group Breast Cancer of GEC-ESTRO. Recommendations from GEC ESTRO Breast Cancer Working Group (I): Target definition and target delineation for accelerated or boost partial breast irradiation using multicatheter interstitial brachytherapy after breast conserving closed cavity surgery. Radiotherapy and Oncology. 2015; 115(3): 342-348.

4. Koulis TA, Phan T, Olivotto IA. Hypofractionated whole breast radiotherapy: current perspectives. Breast Cancer (Dove Med Press). 2015; 27(7): 363-370.

5. Strnad V, Ott OJ, Hildebrandt G, Kauer-Dorner D, Knauerhase H, Major T et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomized, phase 3, non-inferiority trial. Lancet. 2016; 387(10015): 229-238.

6. Veronesi U, Orecchia R, Maisonneuve P, Viale G, Romensz N, Sangalli C et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomized controlled equivalence trial. Lancet Oncol 2013; 14: 1269-1277

7. Vaidya JS, Bulsara L, Wenz F, Joseph D, Saunders C, Massarut S. Pride, prejudice or science: attitudes towards the results of the TARGIT —A trial of targeted intraoperative radiation therapy for breast cancer. Int J Radiat Oncol Biol Phys. 2015; 92(3): 491-497.

8. Poortmans PM, Collette S, Kirkove C, Van Limbergen E, Budach V, Struikmans H et al; EORTC Radiation Oncology and Breast Cancer Groups. Internal mammary and medial supraclavicular irradiation in breast cancer. N Engl J Med. 2015; 373: 317-327.

9. Whelan TJ, Olivotto IA, Parulekar WR, Ackerman I, Chua BH, Nabid A et al; MA.20 Study Investigators. Regional nodal irradiation in early-stage breast cancer. N Engl J Med. 2015; 373 (4): 307-316.

10. Thorsen LB, Offersen BV, Danř H, Berg M, Jensen I, Pedersen AN et al. DBCG-IMN: a population-based cohort study on the effect of internal mammary node irradiation in early node-positive breast cancer. J Clin Oncol. 2015; 34(4): 314-320.

11. Bernier J, Rossier C, Horiot JC. Recent advances in regional treatment of breast carcinoma. Crit Rev Oncol Hematol. 2016; 99: 107-114.

12. ESTRO breast cancer consensus guidelines. ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer, version 1.1 q. Radiotherapy and Oncology. 2016; 118: 205-208.

13. Pernin V, Belin L, Cottu P, Bontemps P, Lemanski C, De La Lande B et al. Late toxicities and outcomes of adjuvant radiotherapy combined with concurrent bevacizumab in patients with triple-negative non-metastatic breast cancer. Br J Radiol. 2015; 88(1048): 20140800.